This article is more than 5 years old. Information may no longer be current.
VIDEO: Genomic risk system may help treat prostate cancer
CHICAGO — The use of a genomic classifier in combination with clinicopathologic variables may provide a valuable prognostic system for distant metastases and better inform treatment options, according to Charles G. Drake, MD, PhD, director of genitourinary oncology and associate director for clinical research at the Herbert Irving Comprehensive Cancer Center.
“If [we] can predict the patients who are going to be more likely to develop metastases later, [we] could use these types of data to hopefully select patients and offer more aggressive therapy upfront,” Drake told HemOnc Today.
In this video, Drake discusses the results of a study that Daniel Eidelberg Spratt, MD, assistant professor at University of Michigan Health System, and colleagues presented at the ASCO annual meeting. The study demonstrated the potential benefit of a clinical-genomic risk system that could help influence treatment decisions in prostate cancer.
“I think this is a very important study,” Drake said. “I think the next step for this is to see how well this is adopted going forward, whether physicians who take care of prostate cancer patients will go forward and use these data to help choose therapies — particularly in the earlier stage — going forward.”
Reference:
Spratt DE, et al. Abstract 5000. Presented at: ASCO Annual Meeting; June 2-6, 2017; Chicago.
Disclosure: Drake reports no relevant financial disclosures.